Targeting JNK to prevent antiretroviral neuropathy

Oncotarget. 2017 Feb 21;8(8):12546-12547. doi: 10.18632/oncotarget.15091.

Author

Nicoletta Galeotti¹

Affiliation

¹ Laboratory of Neuropsychopharmacology, Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.

No abstract available

Keywords: BDNF; JNK; NRTI; Neuroscience; antiretroviral; neuropathic pain.

Publication types

Editorial

MeSH terms

Animals
Anti-Retroviral Agents / adverse effects*
Antiretroviral Therapy, Highly Active / adverse effects*
Enzyme Inhibitors / therapeutic use
HIV Infections / complications*
HIV Infections / drug therapy*
Humans
Incidence
MAP Kinase Kinase 4 / antagonists & inhibitors*
MAP Kinase Kinase 4 / metabolism
Mice
Peripheral Nervous System Diseases / etiology
Peripheral Nervous System Diseases / prevention & control*
Quality of Life
Sensory Receptor Cells / pathology
Signal Transduction

Substances

Anti-Retroviral Agents
Enzyme Inhibitors
MAP Kinase Kinase 4